For biotechnology companies, the path towards commercialising a drug is torturously long and extraordinarily expensive. And while drug compa…
For biotechnology companies, the path towards commercialising a drug is torturously long and extraordinarily expensive. And while drug compa…
Biotechnology company Progen has been forced to dump its plans to merge with fellow life sciences company Avexa after a group of rebel share…
